Hanmi releases simvastin CR tablets

Published: 2009-02-04 06:57:00

Updated: 2009-02-04 06:57:00

Hanmi Pharm said on February 2 that it has launched its new simvastin controlled-release (CR) 20 mg tablets, followed by its best-selling second simvastin series.

According to the company, the advantages of once-daily simvastin CR tablets are that they can often be taken less frequently than i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK